Syed Zaidi, MD
Internal Medicine · Katy, TXNPI 1518933811
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 55 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $466 and has fallen 52.0% since, to $224 in 2025.
Across 55 payments — averaging $23.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$189
- Novo Nordisk$179
- Amgen$179
- Medtronic$156
- Lilly USA, LLC$136
- Johnson & Johnson$91
- plus $386 from 13 others
Across 46 payments — averaging $11,502 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$364K
- Hikma Pharmaceuticals USA$68K
- GSK$61K
- Modernatx, Inc.$18K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$17K
What the payments were for
- Food & beverage$1,315100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 1 | $189 |
| Novo Nordisk | 9 | $179 |
| Amgen | 10 | $179 |
| Medtronic | 1 | $156 |
| Lilly USA, LLC | 8 | $136 |
| Johnson & Johnson | 5 | $91 |
| Pfizer | 4 | $64 |
| Dexcom, Inc. | 2 | $43 |
| Exact Sciences | 2 | $40 |
| AstraZeneca | 2 | $38 |
| Novartis | 2 | $37 |
| Amarin Pharma, Inc. | 2 | $37 |
| Philips North America LLC | 1 | $26 |
| Kyowa Kirin, Inc. | 1 | $23 |
| GSK | 1 | $21 |
| Shire North American Group Inc | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Neos Therapeutics, LP | 1 | $15 |
| Neuronetics, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,315 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 37 | $49,325 |
| MounjaroTirzepatide | 35 | $42,783 |
| FarxigaDapagliflozin Propanediol | 38 | $33,522 |
| EliquisApixaban | 41 | $28,781 |
| TrulicityDulaglutide | 26 | $27,018 |
| XareltoRivaroxaban | 25 | $24,721 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $18,499 |
| JanuviaSitagliptin Phosphate | 11 | $12,862 |
| VascepaIcosapent Ethyl | 17 | $12,724 |
| MyrbetriqMirabegron | 11 | $11,999 |
| EntrestoSacubitril/Valsartan | 14 | $11,977 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $3,483 |
| Oxcarbazepine | 12 | $2,771 |
| Mometasone Furoate | 30 | $2,758 |
| LantusInsulin Glargine,hum.Rec.Anlog | 22 | $2,331 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $136 | $69,80061 claims |
| Novo NordiskOzempic | $179 | $49,32537 claims |
| AstraZenecaFarxiga | $38 | $33,52238 claims |
| PfizerEliquis | $64 | $28,78141 claims |
| Johnson & JohnsonXarelto | $91 | $24,72125 claims |
| GSKTrelegy Ellipta | $21 | $18,49917 claims |
| NovartisEntresto | $37 | $11,97714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Katy
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Mohammed Al-NajjarEl Paso$586K
- Han SchmidlyDallas$465K
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
- Nitin JainHouston$281K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.